TW202135804A - 治療與s1p1受體相關之病況的方法 - Google Patents

治療與s1p1受體相關之病況的方法 Download PDF

Info

Publication number
TW202135804A
TW202135804A TW110100496A TW110100496A TW202135804A TW 202135804 A TW202135804 A TW 202135804A TW 110100496 A TW110100496 A TW 110100496A TW 110100496 A TW110100496 A TW 110100496A TW 202135804 A TW202135804 A TW 202135804A
Authority
TW
Taiwan
Prior art keywords
compound
individual
pharmaceutically acceptable
acceptable salt
salt
Prior art date
Application number
TW110100496A
Other languages
English (en)
Chinese (zh)
Inventor
凱薩琳 Ｍ 克拉絲比
葛普瑞 雅盧瓦利亞
安卓 克里斯多福 衛斯理 司福瑞奇
Original Assignee
美商艾尼納製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾尼納製藥公司 filed Critical 美商艾尼納製藥公司
Publication of TW202135804A publication Critical patent/TW202135804A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steering-Linkage Mechanisms And Four-Wheel Steering (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW110100496A 2020-01-06 2021-01-06 治療與s1p1受體相關之病況的方法 TW202135804A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062957535P 2020-01-06 2020-01-06
US62/957,535 2020-01-06

Publications (1)

Publication Number Publication Date
TW202135804A true TW202135804A (zh) 2021-10-01

Family

ID=76788331

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110100496A TW202135804A (zh) 2020-01-06 2021-01-06 治療與s1p1受體相關之病況的方法

Country Status (12)

Country Link
US (1) US20230338336A1 (enExample)
EP (1) EP4087562A4 (enExample)
JP (1) JP2023509698A (enExample)
KR (1) KR20220124209A (enExample)
CN (1) CN115066242A (enExample)
AU (1) AU2021205465A1 (enExample)
BR (1) BR112022012846A2 (enExample)
CA (1) CA3166828A1 (enExample)
IL (1) IL294071A (enExample)
MX (1) MX2022008342A (enExample)
TW (1) TW202135804A (enExample)
WO (1) WO2021142030A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240065283A (ko) * 2021-09-23 2024-05-14 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법
WO2023135506A1 (en) * 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
KR102541577B1 (ko) 2022-10-21 2023-06-13 주식회사 넥스트젠바이오사이언스 S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469863A2 (en) * 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
CN104311472B9 (zh) * 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
PL2498610T5 (pl) * 2009-11-13 2024-11-04 Receptos Llc Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
HUE036391T2 (hu) * 2009-11-13 2018-07-30 Celgene Int Ii Sarl Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások
CN105130922A (zh) * 2009-11-13 2015-12-09 瑞塞普托斯公司 选择性的杂环1-磷酸鞘氨醇受体调节剂
US9198911B2 (en) * 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
CN110520124A (zh) * 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法

Also Published As

Publication number Publication date
CN115066242A (zh) 2022-09-16
MX2022008342A (es) 2022-08-04
IL294071A (en) 2022-08-01
KR20220124209A (ko) 2022-09-13
EP4087562A4 (en) 2024-01-10
JP2023509698A (ja) 2023-03-09
CA3166828A1 (en) 2021-07-15
US20230338336A1 (en) 2023-10-26
WO2021142030A1 (en) 2021-07-15
BR112022012846A2 (pt) 2022-09-06
EP4087562A1 (en) 2022-11-16
AU2021205465A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
US20230338336A1 (en) Methods of treating conditions related to the s1p1 receptor
US20250295674A1 (en) Neuroactive steroids for treatment of cns-related disorders
JP5264739B2 (ja) ポリグルタミン伸長関連疾患を治療するための塩素グアナベンズ誘導体の使用
JP2022516662A (ja) Ｓ１ｐ１受容体に関連する状態を治療する方法
EP4395779A1 (en) Lou064 for treating multiple sclerosis
TW202110451A (zh) 使用布魯頓酪胺酸激酶抑制劑治療休格倫氏症候群之方法
WO2019186171A1 (en) Treatment of sarcopenic diseases
EP3983016A1 (en) Methods of treating cancer by targeting cold tumors
JP2023502355A (ja) Ｓ１ｐ１受容体に関連する状態を処置する方法
Wernicke et al. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP)
EP3334426A2 (en) Mdm2 inhibitors for treating uveal melanoma
EP3941465B1 (en) Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
JP6776345B2 (ja) 円形脱毛症の治療
HK40080125A (en) Methods of treating conditions related to the s1p1 receptor
TW202114656A (zh) 治療與s1p1 受體相關之病況的方法
Millar et al. Pos0020 efficacy and safety of secukinumab in patients with rotator cuff tendinopathy: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
KR102585038B1 (ko) 렙틴 수용체 길항제 펩타이드를 유효성분으로 함유하는 유방암 치료용 약학적 조성물
Tekgul et al. Lymphocyte subsets in Bell's palsy: immune pathogenesis and outcome prediction
Wernicke et al. Antidepressants: The safety of duloxetine in the long-term treatment of diabetic neuropathic pain
US20240415798A1 (en) Compositions and methods for treating mucositis
US20130261165A1 (en) Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
Khan et al. AB1152 Musculoskeletal manifestation of diabetes mellitus is highly prevalent and is associated with poor diabetic control
HK40110203A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
Guerrero et al. AB1151 Polymyalgia rheumatica. new therapeutic strategy based on low dose of metrotexate plus local infiltration with corticosteroids
HK40085111A (en) Dosage regimen for the treatment of cancer